These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36817122)

  • 21. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
    Noseworthy PA; Yao X; Abraham NS; Sangaralingham LR; McBane RD; Shah ND
    Chest; 2016 Dec; 150(6):1302-1312. PubMed ID: 27938741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.
    Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Nadkarni A; Vo L
    J Manag Care Spec Pharm; 2018 Sep; 24(9):911-920. PubMed ID: 30156450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Ntaios G; Papavasileiou V; Makaritsis K; Vemmos K; Michel P; Lip GYH
    Stroke; 2017 Sep; 48(9):2494-2503. PubMed ID: 28716982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation.
    Adeboyeje G; Sylwestrzak G; Barron JJ; White J; Rosenberg A; Abarca J; Crawford G; Redberg R
    J Manag Care Spec Pharm; 2017 Sep; 23(9):968-978. PubMed ID: 28854073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study.
    Hohnloser SH; Basic E; Nabauer M
    Clin Res Cardiol; 2017 Aug; 106(8):618-628. PubMed ID: 28293797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.
    Deitelzweig S; Keshishian A; Li X; Kang A; Dhamane AD; Luo X; Balachander N; Rosenblatt L; Mardekian J; Pan X; Nadkarni A; Di Fusco M; Garcia Reeves AB; Yuce H; Lip GYH
    J Am Geriatr Soc; 2019 Aug; 67(8):1662-1671. PubMed ID: 31112292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients With Active Cancer.
    Deitelzweig S; Keshishian AV; Zhang Y; Kang A; Dhamane AD; Luo X; Klem C; Ferri M; Jiang J; Yuce H; Lip GYH
    JACC CardioOncol; 2021 Sep; 3(3):411-424. PubMed ID: 34604802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-vitamin K antagonist oral anticoagulants (NOACs) post-percutaneous coronary intervention: a network meta-analysis.
    Al Said S; Alabed S; Kaier K; Tan AR; Bode C; Meerpohl JJ; Duerschmied D
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD013252. PubMed ID: 31858590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry.
    Lip GYH; Kotalczyk A; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Rothman KJ; Marler S; Gurusamy VK; Huisman MV;
    Clin Res Cardiol; 2022 May; 111(5):560-573. PubMed ID: 35294625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.
    Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Nadkarni A; Vo L
    J Manag Care Spec Pharm; 2020 May; 26(5):639-651. PubMed ID: 32347184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation.
    Hohnloser SH; Basic E; Hohmann C; Nabauer M
    Thromb Haemost; 2018 Mar; 118(3):526-538. PubMed ID: 29359278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study.
    Kjerpeseth LJ; Selmer R; Ariansen I; Karlstad Ø; Ellekjær H; Skovlund E
    PLoS One; 2019; 14(8):e0221500. PubMed ID: 31449560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis.
    Tereshchenko LG; Henrikson CA; Cigarroa J; Steinberg JS
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study.
    Rutherford OW; Jonasson C; Ghanima W; Söderdahl F; Halvorsen S
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):75-85. PubMed ID: 31942972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation.
    Rutherford OW; Jonasson C; Ghanima W; Söderdahl F; Halvorsen S
    Heart; 2022 Mar; 108(5):345-352. PubMed ID: 33975877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes After Use of Standard- and Low-Dose Non-Vitamin K Oral Anticoagulants in Asian Patients With Atrial Fibrillation.
    Cho MS; Yun JE; Park JJ; Kim YJ; Lee J; Kim H; Park DW; Nam GB
    Stroke; 2019 Jan; 50(1):110-118. PubMed ID: 30580716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation.
    Chan YH; See LC; Tu HT; Yeh YH; Chang SH; Wu LS; Lee HF; Wang CL; Kuo CF; Kuo CT
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29622587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.